Unsupported Browser
The American College of Surgeons website is not compatible with Internet Explorer 11, IE 11. For the best experience please update your browser.
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your ACS member benefits, participate in College activities, and engage with your ACS colleagues. It's all here.

Become a Member
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your ACS member benefits, participate in College activities, and engage with your ACS colleagues. It's all here.

Membership Benefits
ACS
For Your Patients

ACS Cancer Research Program

ALLIANCE A021806: A Phase III Trial of Perioperative vs. Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Akhil Chawla, MD, Rebecca A. Snyder, MD, MPH, FACS, and Cristina R. Ferrone, MD, FACS

July 1, 2022

Oncologists continue to debate the use of preoperative (neoadjuvant) chemotherapy in patients with resectable pancreatic cancer. Potential benefits and shortcomings of neoadjuvant chemotherapy for pancreatic cancer have been well documented.1,2

Unclear Benefit in Survival

For resectable pancreatic cancer, recent data also have shed light on the lower-than-expected survival outcomes seen in patients receiving multiagent neoadjuvant chemotherapy.3 Data from the SWOG (formerly known as the Southwest Oncology Group) S1505 phase II trial demonstrated a median overall survival time of only 22.4 months in patients treated with mFOLFIRNOX and 23.6 months in patients treated with gemcitabine and nab-paclitaxel.3

These outcomes were strikingly lower than the median overall survival time of 54.4 months seen in the PRODIGE (Partenariat de Recherche en Oncologie Digestive) 24/CCTG PA.6 trial for patients with good performance status who were randomized after R0/R1 resection to receive mFOLFIRINOX in the postoperative or adjuvant setting.4 Furthermore, only 25% of patients treated with neoadjuvant mFOLFIRINOX in the SWOG S1505 trial demonstrated a significant or complete pathologic response on histologic analysis.3

 A noteworthy 36% of all patients did not reach surgery because of disease progression during neoadjuvant therapy.5 These results have raised questions regarding the neoadjuvant treatment strategy for technically resectable patients and have added significant equipoise to the issue.

Latest Trial Seeks to Improve Outcomes

ALLIANCE A021806 (NCT 04340141), a randomized phase III trial to evaluate the use of perioperative therapy in resectable pancreatic cancer, opened to accrual in July 2020. This landmark study aims to better understand the role of perioperative therapy in resectable pancreatic cancer. Patients will be randomized to treatment with perioperative mFOLFIRINOX (perioperative arm) or upfront surgery followed by postoperative mFOLFIRINOX (adjuvant arm). Patients randomized to the perioperative arm undergo eight cycles of neoadjuvant mFOLFIRINOX followed by a curative-intent resection. These patients then will receive four additional cycles of mFOLFIRINOX in the postoperative setting. Patients randomized to the adjuvant arm undergo 12 cycles of adjuvant mFOLFIRINOX following pancreatectomy (Figure 1). This study team plans to enroll 353 patients with resectable pancreatic cancer from the US and Canada.

Figure 1. Schema for ALLIANCE A021806
Figure 1. Schema for ALLIANCE A021806

To qualify for trial enrollment, patients must have biopsy-proven pancreatic adenocarcinoma and imaging must demonstrate resectable disease as defined by the National Comprehensive Cancer Network definition of resectable pancreatic cancer. This definition includes pancreatic cancer in any location within the pancreas without evidence of involvement of the celiac artery, common hepatic artery, superior mesenteric artery, or, if present, a replaced right hepatic artery. Splenic arterial involvement is permitted. Venous involvement of less than or equal to 180° of the portal vein and/or superior mesenteric vein vessel wall with patency of the portal vein/splenic vein confluence also is permitted.

Patients must not have definitive evidence of distant metastases. Patients must have good performance status (ECOG 0 or 1) and be candidates to receive mFOLFIRINOX. All patients who are eligible for the trial undergo a prospective central radiologic eligibility review as a method of quality control to confirm that patients enrolled in the trial fall within a consistent definition of resectable pancreatic cancer.

Opportunity to Improve

The primary endpoint of the trial is 2-year overall survival. The trial also will compare clinical outcomes such as disease-free survival, margin-negative resection rates, tolerability of chemotherapy, and health-related quality of life. To date, accrual has been robust; however, the need for continued support of this trial will be important in order to standardize treatment for this patient population. It is anticipated that the results of this trial will be practice-changing and will establish the standard of care for patients with resectable pancreatic cancer.

For more information, contact study cochairs Cristina Ferrone (CFerrone@mgh.harvard.edu) and Akhil Chawla (Akhil.Chawla@northwestern.edu). 


References
  1. Chawla A, Ferrone CR. Neoadjuvant therapy for resectable pancreatic cancer: An evolving paradigm shift. Front Oncol. 2019;9:1085. 
  2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology, Pancreatic Adenocarcinoma Version 1.2022. Available at: https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendations/GetFileFromFileManager?fileManagerId=13584. Accessed May 01, 2022.
  3. Sohal D, Duong MT, Ahmad SA, et al. SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). J Clin Oncol. 2020;38(15_suppl):4504. 
  4. Conroy T, Hammel P, Turpin A, et al. LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC). Ann Surg Oncol. 2021;32:S1334. 
  5. 5. Ahmad SA, Duong M, Sohal DPS, et al. Surgical outcome results from SWOG s1505: A randomized clinical trial of mFOLFIRINOX versus gemcitabine/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. Ann Surg. 2020;272(3):481-486. 

Dr. Akhil Chawla is a hepatopancreatobiliary surgical oncologist at Northwestern Medicine and clinical assistant professor of surgery, Northwestern University Feinberg School of Medicine, Chicago, IL. He is co-chair, Alliance A021806 Clinical Trial.